Global Omalizumab Monoclonal Antibody Biosimilars Market Growth 2026-2032
The global Omalizumab Monoclonal Antibody Biosimilars market size is predicted to grow from US$ 284 million in 2025 to US$ 598 million in 2032; it is expected to grow at a CAGR of 11.7% from 2026 to 2032.
In 2025, global Omalizumab Monoclonal Antibody Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab monoclonal antibody biosimilar is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (Fc?RI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The market is entering a rapid commercialization stage
As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.
Price competition will become increasingly important
As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.
Interchangeability will become a key competitive advantage
In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.
More dosage forms and specifications will be introduced
Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.
Expansion of indications will increase long-term market potential
As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.
LP Information, Inc. (LPI) ' newest research report, the ?Omalizumab Monoclonal Antibody Biosimilars Industry Forecast? looks at past sales and reviews total world Omalizumab Monoclonal Antibody Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Omalizumab Monoclonal Antibody Biosimilars sales for 2026 through 2032. With Omalizumab Monoclonal Antibody Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Omalizumab Monoclonal Antibody Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Omalizumab Monoclonal Antibody Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Omalizumab Monoclonal Antibody Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Omalizumab Monoclonal Antibody Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Omalizumab Monoclonal Antibody Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Omalizumab Monoclonal Antibody Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Omalizumab Monoclonal Antibody Biosimilars market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
In 2025, global Omalizumab Monoclonal Antibody Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab monoclonal antibody biosimilar is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (Fc?RI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The market is entering a rapid commercialization stage
As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.
Price competition will become increasingly important
As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.
Interchangeability will become a key competitive advantage
In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.
More dosage forms and specifications will be introduced
Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.
Expansion of indications will increase long-term market potential
As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.
LP Information, Inc. (LPI) ' newest research report, the ?Omalizumab Monoclonal Antibody Biosimilars Industry Forecast? looks at past sales and reviews total world Omalizumab Monoclonal Antibody Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Omalizumab Monoclonal Antibody Biosimilars sales for 2026 through 2032. With Omalizumab Monoclonal Antibody Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Omalizumab Monoclonal Antibody Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Omalizumab Monoclonal Antibody Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Omalizumab Monoclonal Antibody Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Omalizumab Monoclonal Antibody Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Omalizumab Monoclonal Antibody Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Omalizumab Monoclonal Antibody Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Omalizumab Monoclonal Antibody Biosimilars market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 150 mg/mL
- 75 mg/0.5 mL
- For Adults
- For Teenagers
- For Children
- Every 2 Weeks
- Every 4 Weeks
- Individualized Dosing Regimen
- Persistent Asthma
- Nasal Polyps
- Chronic Idiopathic Urticaria
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Novartis
- Glenmark Pharmaceuticals
- Selexis
- Generium
- CuraTeQ
- Celltrion Healthcare
- Alvotech
- BiosanaPharma
- Mabpharm
- CSPC Pharmaceutical Group
- Biomabs
- HisunPharm
- What is the 10-year outlook for the global Omalizumab Monoclonal Antibody Biosimilars market?
- What factors are driving Omalizumab Monoclonal Antibody Biosimilars market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How doOmalizumab Monoclonal Antibody Biosimilars market opportunities vary by end market size?
- How does Omalizumab Monoclonal Antibody Biosimilars break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Omalizumab Monoclonal Antibody Biosimilars by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Omalizumab Monoclonal Antibody Biosimilars by Country/Region, 2021, 2025 & 2032
2.2 Omalizumab Monoclonal Antibody Biosimilars Segment by Type
2.2.1 150 mg/mL
2.2.2 75 mg/0.5 mL
2.2.3 Omalizumab Monoclonal Antibody Biosimilars Sales by Type
2.2.3.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
2.2.3.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Type (2021-2026)
2.3 Omalizumab Monoclonal Antibody Biosimilars Segment by Age
2.3.1 For Adults
2.3.2 For Teenagers
2.3.3 For Children
2.3.4 Omalizumab Monoclonal Antibody Biosimilars Sales by Age
2.3.4.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Age (2021-2026)
2.3.4.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue and Market Share by Age (2021-2026)
2.3.4.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Age (2021-2026)
2.4 Omalizumab Monoclonal Antibody Biosimilars Segment by Frequency
2.4.1 Every 2 Weeks
2.4.2 Every 4 Weeks
2.4.3 Individualized Dosing Regimen
2.4.4 Omalizumab Monoclonal Antibody Biosimilars Sales by Frequency
2.4.4.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Frequency (2021-2026)
2.4.4.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue and Market Share by Frequency (2021-2026)
2.4.4.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Frequency (2021-2026)
2.5 Omalizumab Monoclonal Antibody Biosimilars Segment by Application
2.5.1 Persistent Asthma
2.5.2 Nasal Polyps
2.5.3 Chronic Idiopathic Urticaria
2.5.4 Omalizumab Monoclonal Antibody Biosimilars Sales by Application
2.5.4.1 Global Omalizumab Monoclonal Antibody Biosimilars Sale Market Share by Application (2021-2026)
2.5.4.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Omalizumab Monoclonal Antibody Biosimilars Breakdown Data by Company
3.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Annual Sales by Company (2021-2026)
3.1.2 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Company (2021-2026)
3.2 Global Omalizumab Monoclonal Antibody Biosimilars Annual Revenue by Company (2021-2026)
3.2.1 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Company (2021-2026)
3.2.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Company (2021-2026)
3.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Company
3.4 Key Manufacturers Omalizumab Monoclonal Antibody Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Omalizumab Monoclonal Antibody Biosimilars Product Location Distribution
3.4.2 Players Omalizumab Monoclonal Antibody Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR OMALIZUMAB MONOCLONAL ANTIBODY BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Omalizumab Monoclonal Antibody Biosimilars Market Size by Geographic Region (2021-2026)
4.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Omalizumab Monoclonal Antibody Biosimilars Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Omalizumab Monoclonal Antibody Biosimilars Market Size by Country/Region (2021-2026)
4.2.1 Global Omalizumab Monoclonal Antibody Biosimilars Annual Sales by Country/Region (2021-2026)
4.2.2 Global Omalizumab Monoclonal Antibody Biosimilars Annual Revenue by Country/Region (2021-2026)
4.3 Americas Omalizumab Monoclonal Antibody Biosimilars Sales Growth
4.4 APAC Omalizumab Monoclonal Antibody Biosimilars Sales Growth
4.5 Europe Omalizumab Monoclonal Antibody Biosimilars Sales Growth
4.6 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Country
5.1.1 Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026)
5.1.2 Americas Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026)
5.2 Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026)
5.3 Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Region
6.1.1 APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Region (2021-2026)
6.1.2 APAC Omalizumab Monoclonal Antibody Biosimilars Revenue by Region (2021-2026)
6.2 APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026)
6.3 APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Omalizumab Monoclonal Antibody Biosimilars by Country
7.1.1 Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026)
7.1.2 Europe Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026)
7.2 Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026)
7.3 Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars by Country
8.1.1 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026)
8.1.2 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026)
8.2 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026)
8.3 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Omalizumab Monoclonal Antibody Biosimilars
10.3 Manufacturing Process Analysis of Omalizumab Monoclonal Antibody Biosimilars
10.4 Industry Chain Structure of Omalizumab Monoclonal Antibody Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Omalizumab Monoclonal Antibody Biosimilars Distributors
11.3 Omalizumab Monoclonal Antibody Biosimilars Customer
12 WORLD FORECAST REVIEW FOR OMALIZUMAB MONOCLONAL ANTIBODY BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Omalizumab Monoclonal Antibody Biosimilars Market Size Forecast by Region
12.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Forecast by Region (2027-2032)
12.1.2 Global Omalizumab Monoclonal Antibody Biosimilars Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Omalizumab Monoclonal Antibody Biosimilars Forecast by Type (2027-2032)
12.7 Global Omalizumab Monoclonal Antibody Biosimilars Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.1.3 Roche Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.2.3 Novartis Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Glenmark Pharmaceuticals
13.3.1 Glenmark Pharmaceuticals Company Information
13.3.2 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.3.3 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Glenmark Pharmaceuticals Main Business Overview
13.3.5 Glenmark Pharmaceuticals Latest Developments
13.4 Selexis
13.4.1 Selexis Company Information
13.4.2 Selexis Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.4.3 Selexis Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Selexis Main Business Overview
13.4.5 Selexis Latest Developments
13.5 Generium
13.5.1 Generium Company Information
13.5.2 Generium Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.5.3 Generium Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Generium Main Business Overview
13.5.5 Generium Latest Developments
13.6 CuraTeQ
13.6.1 CuraTeQ Company Information
13.6.2 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.6.3 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CuraTeQ Main Business Overview
13.6.5 CuraTeQ Latest Developments
13.7 Celltrion Healthcare
13.7.1 Celltrion Healthcare Company Information
13.7.2 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.7.3 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Celltrion Healthcare Main Business Overview
13.7.5 Celltrion Healthcare Latest Developments
13.8 Alvotech
13.8.1 Alvotech Company Information
13.8.2 Alvotech Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.8.3 Alvotech Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Alvotech Main Business Overview
13.8.5 Alvotech Latest Developments
13.9 BiosanaPharma
13.9.1 BiosanaPharma Company Information
13.9.2 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.9.3 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 BiosanaPharma Main Business Overview
13.9.5 BiosanaPharma Latest Developments
13.10 Mabpharm
13.10.1 Mabpharm Company Information
13.10.2 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.10.3 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Mabpharm Main Business Overview
13.10.5 Mabpharm Latest Developments
13.11 CSPC Pharmaceutical Group
13.11.1 CSPC Pharmaceutical Group Company Information
13.11.2 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.11.3 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 CSPC Pharmaceutical Group Main Business Overview
13.11.5 CSPC Pharmaceutical Group Latest Developments
13.12 Biomabs
13.12.1 Biomabs Company Information
13.12.2 Biomabs Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.12.3 Biomabs Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Biomabs Main Business Overview
13.12.5 Biomabs Latest Developments
13.13 HisunPharm
13.13.1 HisunPharm Company Information
13.13.2 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.13.3 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 HisunPharm Main Business Overview
13.13.5 HisunPharm Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Omalizumab Monoclonal Antibody Biosimilars by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Omalizumab Monoclonal Antibody Biosimilars by Country/Region, 2021, 2025 & 2032
2.2 Omalizumab Monoclonal Antibody Biosimilars Segment by Type
2.2.1 150 mg/mL
2.2.2 75 mg/0.5 mL
2.2.3 Omalizumab Monoclonal Antibody Biosimilars Sales by Type
2.2.3.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
2.2.3.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Type (2021-2026)
2.3 Omalizumab Monoclonal Antibody Biosimilars Segment by Age
2.3.1 For Adults
2.3.2 For Teenagers
2.3.3 For Children
2.3.4 Omalizumab Monoclonal Antibody Biosimilars Sales by Age
2.3.4.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Age (2021-2026)
2.3.4.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue and Market Share by Age (2021-2026)
2.3.4.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Age (2021-2026)
2.4 Omalizumab Monoclonal Antibody Biosimilars Segment by Frequency
2.4.1 Every 2 Weeks
2.4.2 Every 4 Weeks
2.4.3 Individualized Dosing Regimen
2.4.4 Omalizumab Monoclonal Antibody Biosimilars Sales by Frequency
2.4.4.1 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Frequency (2021-2026)
2.4.4.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue and Market Share by Frequency (2021-2026)
2.4.4.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Frequency (2021-2026)
2.5 Omalizumab Monoclonal Antibody Biosimilars Segment by Application
2.5.1 Persistent Asthma
2.5.2 Nasal Polyps
2.5.3 Chronic Idiopathic Urticaria
2.5.4 Omalizumab Monoclonal Antibody Biosimilars Sales by Application
2.5.4.1 Global Omalizumab Monoclonal Antibody Biosimilars Sale Market Share by Application (2021-2026)
2.5.4.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Omalizumab Monoclonal Antibody Biosimilars Breakdown Data by Company
3.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Annual Sales by Company (2021-2026)
3.1.2 Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Company (2021-2026)
3.2 Global Omalizumab Monoclonal Antibody Biosimilars Annual Revenue by Company (2021-2026)
3.2.1 Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Company (2021-2026)
3.2.2 Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Company (2021-2026)
3.3 Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Company
3.4 Key Manufacturers Omalizumab Monoclonal Antibody Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Omalizumab Monoclonal Antibody Biosimilars Product Location Distribution
3.4.2 Players Omalizumab Monoclonal Antibody Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR OMALIZUMAB MONOCLONAL ANTIBODY BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Omalizumab Monoclonal Antibody Biosimilars Market Size by Geographic Region (2021-2026)
4.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Omalizumab Monoclonal Antibody Biosimilars Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Omalizumab Monoclonal Antibody Biosimilars Market Size by Country/Region (2021-2026)
4.2.1 Global Omalizumab Monoclonal Antibody Biosimilars Annual Sales by Country/Region (2021-2026)
4.2.2 Global Omalizumab Monoclonal Antibody Biosimilars Annual Revenue by Country/Region (2021-2026)
4.3 Americas Omalizumab Monoclonal Antibody Biosimilars Sales Growth
4.4 APAC Omalizumab Monoclonal Antibody Biosimilars Sales Growth
4.5 Europe Omalizumab Monoclonal Antibody Biosimilars Sales Growth
4.6 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Country
5.1.1 Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026)
5.1.2 Americas Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026)
5.2 Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026)
5.3 Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Region
6.1.1 APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Region (2021-2026)
6.1.2 APAC Omalizumab Monoclonal Antibody Biosimilars Revenue by Region (2021-2026)
6.2 APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026)
6.3 APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Omalizumab Monoclonal Antibody Biosimilars by Country
7.1.1 Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026)
7.1.2 Europe Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026)
7.2 Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026)
7.3 Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars by Country
8.1.1 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026)
8.1.2 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026)
8.2 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026)
8.3 Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Omalizumab Monoclonal Antibody Biosimilars
10.3 Manufacturing Process Analysis of Omalizumab Monoclonal Antibody Biosimilars
10.4 Industry Chain Structure of Omalizumab Monoclonal Antibody Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Omalizumab Monoclonal Antibody Biosimilars Distributors
11.3 Omalizumab Monoclonal Antibody Biosimilars Customer
12 WORLD FORECAST REVIEW FOR OMALIZUMAB MONOCLONAL ANTIBODY BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Omalizumab Monoclonal Antibody Biosimilars Market Size Forecast by Region
12.1.1 Global Omalizumab Monoclonal Antibody Biosimilars Forecast by Region (2027-2032)
12.1.2 Global Omalizumab Monoclonal Antibody Biosimilars Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Omalizumab Monoclonal Antibody Biosimilars Forecast by Type (2027-2032)
12.7 Global Omalizumab Monoclonal Antibody Biosimilars Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.1.3 Roche Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.2.3 Novartis Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Glenmark Pharmaceuticals
13.3.1 Glenmark Pharmaceuticals Company Information
13.3.2 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.3.3 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Glenmark Pharmaceuticals Main Business Overview
13.3.5 Glenmark Pharmaceuticals Latest Developments
13.4 Selexis
13.4.1 Selexis Company Information
13.4.2 Selexis Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.4.3 Selexis Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Selexis Main Business Overview
13.4.5 Selexis Latest Developments
13.5 Generium
13.5.1 Generium Company Information
13.5.2 Generium Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.5.3 Generium Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Generium Main Business Overview
13.5.5 Generium Latest Developments
13.6 CuraTeQ
13.6.1 CuraTeQ Company Information
13.6.2 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.6.3 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CuraTeQ Main Business Overview
13.6.5 CuraTeQ Latest Developments
13.7 Celltrion Healthcare
13.7.1 Celltrion Healthcare Company Information
13.7.2 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.7.3 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Celltrion Healthcare Main Business Overview
13.7.5 Celltrion Healthcare Latest Developments
13.8 Alvotech
13.8.1 Alvotech Company Information
13.8.2 Alvotech Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.8.3 Alvotech Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Alvotech Main Business Overview
13.8.5 Alvotech Latest Developments
13.9 BiosanaPharma
13.9.1 BiosanaPharma Company Information
13.9.2 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.9.3 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 BiosanaPharma Main Business Overview
13.9.5 BiosanaPharma Latest Developments
13.10 Mabpharm
13.10.1 Mabpharm Company Information
13.10.2 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.10.3 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Mabpharm Main Business Overview
13.10.5 Mabpharm Latest Developments
13.11 CSPC Pharmaceutical Group
13.11.1 CSPC Pharmaceutical Group Company Information
13.11.2 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.11.3 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 CSPC Pharmaceutical Group Main Business Overview
13.11.5 CSPC Pharmaceutical Group Latest Developments
13.12 Biomabs
13.12.1 Biomabs Company Information
13.12.2 Biomabs Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.12.3 Biomabs Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Biomabs Main Business Overview
13.12.5 Biomabs Latest Developments
13.13 HisunPharm
13.13.1 HisunPharm Company Information
13.13.2 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
13.13.3 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 HisunPharm Main Business Overview
13.13.5 HisunPharm Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Omalizumab Monoclonal Antibody Biosimilars Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Omalizumab Monoclonal Antibody Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 150 mg/mL
Table 4. Major Players of 75 mg/0.5 mL
Table 5. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 6. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Table 7. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Type (2021-2026) & ($ million)
Table 8. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Type (2021-2026)
Table 9. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of For Adults
Table 11. Major Players of For Teenagers
Table 12. Major Players of For Children
Table 13. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Age (2021-2026) & (K Dose)
Table 14. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Age (2021-2026)
Table 15. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Age (2021-2026) & ($ million)
Table 16. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Age (2021-2026)
Table 17. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Age (2021-2026) & (US$/Dose)
Table 18. Major Players of Every 2 Weeks
Table 19. Major Players of Every 4 Weeks
Table 20. Major Players of Individualized Dosing Regimen
Table 21. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Frequency (2021-2026) & (K Dose)
Table 22. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Frequency (2021-2026)
Table 23. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Frequency (2021-2026) & ($ million)
Table 24. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Frequency (2021-2026)
Table 25. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Frequency (2021-2026) & (US$/Dose)
Table 26. Global Omalizumab Monoclonal Antibody Biosimilars Sale by Application (2021-2026) & (K Dose)
Table 27. Global Omalizumab Monoclonal Antibody Biosimilars Sale Market Share by Application (2021-2026)
Table 28. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Application (2021-2026) & ($ million)
Table 29. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Application (2021-2026)
Table 30. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Company (2021-2026) & (K Dose)
Table 32. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Company (2021-2026)
Table 33. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Company (2021-2026)
Table 35. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers Omalizumab Monoclonal Antibody Biosimilars Producing Area Distribution and Sales Area
Table 37. Players Omalizumab Monoclonal Antibody Biosimilars Products Offered
Table 38. Omalizumab Monoclonal Antibody Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Geographic Region (2021-2026) & (K Dose)
Table 42. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share Geographic Region (2021-2026)
Table 43. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Country/Region (2021-2026) & (K Dose)
Table 46. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country/Region (2021-2026)
Table 47. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026) & (K Dose)
Table 50. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country (2021-2026)
Table 51. Americas Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 53. Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026) & (K Dose)
Table 54. APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Region (2021-2026) & (K Dose)
Table 55. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Region (2021-2026)
Table 56. APAC Omalizumab Monoclonal Antibody Biosimilars Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 58. APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026) & (K Dose)
Table 59. Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026) & (K Dose)
Table 60. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 62. Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026) & (K Dose)
Table 63. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026) & (K Dose)
Table 64. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 66. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026) & (K Dose)
Table 67. Key Market Drivers & Growth Opportunities of Omalizumab Monoclonal Antibody Biosimilars
Table 68. Key Market Challenges & Risks of Omalizumab Monoclonal Antibody Biosimilars
Table 69. Key Industry Trends of Omalizumab Monoclonal Antibody Biosimilars
Table 70. Omalizumab Monoclonal Antibody Biosimilars Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Omalizumab Monoclonal Antibody Biosimilars Distributors List
Table 73. Omalizumab Monoclonal Antibody Biosimilars Customer List
Table 74. Global Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Region (2027-2032) & (K Dose)
Table 75. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Country (2027-2032) & (K Dose)
Table 77. Americas Omalizumab Monoclonal Antibody Biosimilars Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Region (2027-2032) & (K Dose)
Table 79. APAC Omalizumab Monoclonal Antibody Biosimilars Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Country (2027-2032) & (K Dose)
Table 81. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Type (2027-2032) & (K Dose)
Table 85. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Application (2027-2032) & (K Dose)
Table 87. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Roche Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 89. Roche Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 90. Roche Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Roche Main Business
Table 92. Roche Latest Developments
Table 93. Novartis Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 95. Novartis Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. Novartis Main Business
Table 97. Novartis Latest Developments
Table 98. Glenmark Pharmaceuticals Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 99. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 100. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Glenmark Pharmaceuticals Main Business
Table 102. Glenmark Pharmaceuticals Latest Developments
Table 103. Selexis Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 104. Selexis Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 105. Selexis Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Selexis Main Business
Table 107. Selexis Latest Developments
Table 108. Generium Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 109. Generium Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 110. Generium Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Generium Main Business
Table 112. Generium Latest Developments
Table 113. CuraTeQ Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 114. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 115. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. CuraTeQ Main Business
Table 117. CuraTeQ Latest Developments
Table 118. Celltrion Healthcare Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 119. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 120. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Celltrion Healthcare Main Business
Table 122. Celltrion Healthcare Latest Developments
Table 123. Alvotech Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 124. Alvotech Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 125. Alvotech Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Alvotech Main Business
Table 127. Alvotech Latest Developments
Table 128. BiosanaPharma Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 129. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 130. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. BiosanaPharma Main Business
Table 132. BiosanaPharma Latest Developments
Table 133. Mabpharm Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 134. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 135. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. Mabpharm Main Business
Table 137. Mabpharm Latest Developments
Table 138. CSPC Pharmaceutical Group Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 139. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 140. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 141. CSPC Pharmaceutical Group Main Business
Table 142. CSPC Pharmaceutical Group Latest Developments
Table 143. Biomabs Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 144. Biomabs Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 145. Biomabs Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 146. Biomabs Main Business
Table 147. Biomabs Latest Developments
Table 148. HisunPharm Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 149. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 150. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 151. HisunPharm Main Business
Table 152. HisunPharm Latest Developments
Table 1. Omalizumab Monoclonal Antibody Biosimilars Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Omalizumab Monoclonal Antibody Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 150 mg/mL
Table 4. Major Players of 75 mg/0.5 mL
Table 5. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 6. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Table 7. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Type (2021-2026) & ($ million)
Table 8. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Type (2021-2026)
Table 9. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of For Adults
Table 11. Major Players of For Teenagers
Table 12. Major Players of For Children
Table 13. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Age (2021-2026) & (K Dose)
Table 14. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Age (2021-2026)
Table 15. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Age (2021-2026) & ($ million)
Table 16. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Age (2021-2026)
Table 17. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Age (2021-2026) & (US$/Dose)
Table 18. Major Players of Every 2 Weeks
Table 19. Major Players of Every 4 Weeks
Table 20. Major Players of Individualized Dosing Regimen
Table 21. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Frequency (2021-2026) & (K Dose)
Table 22. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Frequency (2021-2026)
Table 23. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Frequency (2021-2026) & ($ million)
Table 24. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Frequency (2021-2026)
Table 25. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Frequency (2021-2026) & (US$/Dose)
Table 26. Global Omalizumab Monoclonal Antibody Biosimilars Sale by Application (2021-2026) & (K Dose)
Table 27. Global Omalizumab Monoclonal Antibody Biosimilars Sale Market Share by Application (2021-2026)
Table 28. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Application (2021-2026) & ($ million)
Table 29. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Application (2021-2026)
Table 30. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Company (2021-2026) & (K Dose)
Table 32. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Company (2021-2026)
Table 33. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Company (2021-2026)
Table 35. Global Omalizumab Monoclonal Antibody Biosimilars Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers Omalizumab Monoclonal Antibody Biosimilars Producing Area Distribution and Sales Area
Table 37. Players Omalizumab Monoclonal Antibody Biosimilars Products Offered
Table 38. Omalizumab Monoclonal Antibody Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Geographic Region (2021-2026) & (K Dose)
Table 42. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share Geographic Region (2021-2026)
Table 43. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Omalizumab Monoclonal Antibody Biosimilars Sales by Country/Region (2021-2026) & (K Dose)
Table 46. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country/Region (2021-2026)
Table 47. Global Omalizumab Monoclonal Antibody Biosimilars Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026) & (K Dose)
Table 50. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country (2021-2026)
Table 51. Americas Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 53. Americas Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026) & (K Dose)
Table 54. APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Region (2021-2026) & (K Dose)
Table 55. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Region (2021-2026)
Table 56. APAC Omalizumab Monoclonal Antibody Biosimilars Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 58. APAC Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026) & (K Dose)
Table 59. Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026) & (K Dose)
Table 60. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 62. Europe Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026) & (K Dose)
Table 63. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Country (2021-2026) & (K Dose)
Table 64. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Type (2021-2026) & (K Dose)
Table 66. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales by Application (2021-2026) & (K Dose)
Table 67. Key Market Drivers & Growth Opportunities of Omalizumab Monoclonal Antibody Biosimilars
Table 68. Key Market Challenges & Risks of Omalizumab Monoclonal Antibody Biosimilars
Table 69. Key Industry Trends of Omalizumab Monoclonal Antibody Biosimilars
Table 70. Omalizumab Monoclonal Antibody Biosimilars Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Omalizumab Monoclonal Antibody Biosimilars Distributors List
Table 73. Omalizumab Monoclonal Antibody Biosimilars Customer List
Table 74. Global Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Region (2027-2032) & (K Dose)
Table 75. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Country (2027-2032) & (K Dose)
Table 77. Americas Omalizumab Monoclonal Antibody Biosimilars Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Region (2027-2032) & (K Dose)
Table 79. APAC Omalizumab Monoclonal Antibody Biosimilars Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Country (2027-2032) & (K Dose)
Table 81. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Type (2027-2032) & (K Dose)
Table 85. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Omalizumab Monoclonal Antibody Biosimilars Sales Forecast by Application (2027-2032) & (K Dose)
Table 87. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Roche Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 89. Roche Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 90. Roche Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Roche Main Business
Table 92. Roche Latest Developments
Table 93. Novartis Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 95. Novartis Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. Novartis Main Business
Table 97. Novartis Latest Developments
Table 98. Glenmark Pharmaceuticals Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 99. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 100. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Glenmark Pharmaceuticals Main Business
Table 102. Glenmark Pharmaceuticals Latest Developments
Table 103. Selexis Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 104. Selexis Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 105. Selexis Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Selexis Main Business
Table 107. Selexis Latest Developments
Table 108. Generium Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 109. Generium Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 110. Generium Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Generium Main Business
Table 112. Generium Latest Developments
Table 113. CuraTeQ Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 114. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 115. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. CuraTeQ Main Business
Table 117. CuraTeQ Latest Developments
Table 118. Celltrion Healthcare Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 119. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 120. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Celltrion Healthcare Main Business
Table 122. Celltrion Healthcare Latest Developments
Table 123. Alvotech Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 124. Alvotech Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 125. Alvotech Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Alvotech Main Business
Table 127. Alvotech Latest Developments
Table 128. BiosanaPharma Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 129. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 130. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. BiosanaPharma Main Business
Table 132. BiosanaPharma Latest Developments
Table 133. Mabpharm Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 134. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 135. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. Mabpharm Main Business
Table 137. Mabpharm Latest Developments
Table 138. CSPC Pharmaceutical Group Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 139. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 140. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 141. CSPC Pharmaceutical Group Main Business
Table 142. CSPC Pharmaceutical Group Latest Developments
Table 143. Biomabs Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 144. Biomabs Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 145. Biomabs Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 146. Biomabs Main Business
Table 147. Biomabs Latest Developments
Table 148. HisunPharm Basic Information, Omalizumab Monoclonal Antibody Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 149. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product Portfolios and Specifications
Table 150. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 151. HisunPharm Main Business
Table 152. HisunPharm Latest Developments
LIST OF FIGURES
Figure 1. Picture of Omalizumab Monoclonal Antibody Biosimilars
Figure 2. Omalizumab Monoclonal Antibody Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Omalizumab Monoclonal Antibody Biosimilars Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Omalizumab Monoclonal Antibody Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country/Region (2025)
Figure 10. Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 150 mg/mL
Figure 12. Product Picture of 75 mg/0.5 mL
Figure 13. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type in 2026
Figure 14. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of For Adults
Figure 16. Product Picture of For Teenagers
Figure 17. Product Picture of For Children
Figure 18. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Age in 2026
Figure 19. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Age (2021-2026)
Figure 20. Product Picture of Every 2 Weeks
Figure 21. Product Picture of Every 4 Weeks
Figure 22. Product Picture of Individualized Dosing Regimen
Figure 23. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Frequency in 2026
Figure 24. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Frequency (2021-2026)
Figure 25. Omalizumab Monoclonal Antibody Biosimilars Consumed in Persistent Asthma
Figure 26. Global Omalizumab Monoclonal Antibody Biosimilars Market: Persistent Asthma (2021-2026) & (K Dose)
Figure 27. Omalizumab Monoclonal Antibody Biosimilars Consumed in Nasal Polyps
Figure 28. Global Omalizumab Monoclonal Antibody Biosimilars Market: Nasal Polyps (2021-2026) & (K Dose)
Figure 29. Omalizumab Monoclonal Antibody Biosimilars Consumed in Chronic Idiopathic Urticaria
Figure 30. Global Omalizumab Monoclonal Antibody Biosimilars Market: Chronic Idiopathic Urticaria (2021-2026) & (K Dose)
Figure 31. Global Omalizumab Monoclonal Antibody Biosimilars Sale Market Share by Application (2025)
Figure 32. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Application in 2025
Figure 33. Omalizumab Monoclonal Antibody Biosimilars Sales by Company in 2025 (K Dose)
Figure 34. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Company in 2025
Figure 35. Omalizumab Monoclonal Antibody Biosimilars Revenue by Company in 2025 ($ millions)
Figure 36. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Company in 2025
Figure 37. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Omalizumab Monoclonal Antibody Biosimilars Sales 2021-2026 (K Dose)
Figure 40. Americas Omalizumab Monoclonal Antibody Biosimilars Revenue 2021-2026 ($ millions)
Figure 41. APAC Omalizumab Monoclonal Antibody Biosimilars Sales 2021-2026 (K Dose)
Figure 42. APAC Omalizumab Monoclonal Antibody Biosimilars Revenue 2021-2026 ($ millions)
Figure 43. Europe Omalizumab Monoclonal Antibody Biosimilars Sales 2021-2026 (K Dose)
Figure 44. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales 2021-2026 (K Dose)
Figure 46. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue 2021-2026 ($ millions)
Figure 47. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country in 2025
Figure 48. Americas Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2021-2026)
Figure 49. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Figure 50. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2021-2026)
Figure 51. United States Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Region in 2025
Figure 56. APAC Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Region (2021-2026)
Figure 57. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Figure 58. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2021-2026)
Figure 59. China Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 63. India Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country in 2025
Figure 67. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2021-2026)
Figure 68. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Figure 69. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2021-2026)
Figure 70. Germany Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 71. France Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2021-2026)
Figure 78. Egypt Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Omalizumab Monoclonal Antibody Biosimilars in 2026
Figure 84. Manufacturing Process Analysis of Omalizumab Monoclonal Antibody Biosimilars
Figure 85. Industry Chain Structure of Omalizumab Monoclonal Antibody Biosimilars
Figure 86. Channels of Distribution
Figure 87. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Forecast by Region (2027-2032)
Figure 88. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Omalizumab Monoclonal Antibody Biosimilars
Figure 2. Omalizumab Monoclonal Antibody Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Omalizumab Monoclonal Antibody Biosimilars Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Omalizumab Monoclonal Antibody Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country/Region (2025)
Figure 10. Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 150 mg/mL
Figure 12. Product Picture of 75 mg/0.5 mL
Figure 13. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type in 2026
Figure 14. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of For Adults
Figure 16. Product Picture of For Teenagers
Figure 17. Product Picture of For Children
Figure 18. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Age in 2026
Figure 19. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Age (2021-2026)
Figure 20. Product Picture of Every 2 Weeks
Figure 21. Product Picture of Every 4 Weeks
Figure 22. Product Picture of Individualized Dosing Regimen
Figure 23. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Frequency in 2026
Figure 24. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Frequency (2021-2026)
Figure 25. Omalizumab Monoclonal Antibody Biosimilars Consumed in Persistent Asthma
Figure 26. Global Omalizumab Monoclonal Antibody Biosimilars Market: Persistent Asthma (2021-2026) & (K Dose)
Figure 27. Omalizumab Monoclonal Antibody Biosimilars Consumed in Nasal Polyps
Figure 28. Global Omalizumab Monoclonal Antibody Biosimilars Market: Nasal Polyps (2021-2026) & (K Dose)
Figure 29. Omalizumab Monoclonal Antibody Biosimilars Consumed in Chronic Idiopathic Urticaria
Figure 30. Global Omalizumab Monoclonal Antibody Biosimilars Market: Chronic Idiopathic Urticaria (2021-2026) & (K Dose)
Figure 31. Global Omalizumab Monoclonal Antibody Biosimilars Sale Market Share by Application (2025)
Figure 32. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Application in 2025
Figure 33. Omalizumab Monoclonal Antibody Biosimilars Sales by Company in 2025 (K Dose)
Figure 34. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Company in 2025
Figure 35. Omalizumab Monoclonal Antibody Biosimilars Revenue by Company in 2025 ($ millions)
Figure 36. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Company in 2025
Figure 37. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Omalizumab Monoclonal Antibody Biosimilars Sales 2021-2026 (K Dose)
Figure 40. Americas Omalizumab Monoclonal Antibody Biosimilars Revenue 2021-2026 ($ millions)
Figure 41. APAC Omalizumab Monoclonal Antibody Biosimilars Sales 2021-2026 (K Dose)
Figure 42. APAC Omalizumab Monoclonal Antibody Biosimilars Revenue 2021-2026 ($ millions)
Figure 43. Europe Omalizumab Monoclonal Antibody Biosimilars Sales 2021-2026 (K Dose)
Figure 44. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales 2021-2026 (K Dose)
Figure 46. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Revenue 2021-2026 ($ millions)
Figure 47. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country in 2025
Figure 48. Americas Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2021-2026)
Figure 49. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Figure 50. Americas Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2021-2026)
Figure 51. United States Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Region in 2025
Figure 56. APAC Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Region (2021-2026)
Figure 57. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Figure 58. APAC Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2021-2026)
Figure 59. China Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 63. India Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country in 2025
Figure 67. Europe Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share by Country (2021-2026)
Figure 68. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Figure 69. Europe Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2021-2026)
Figure 70. Germany Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 71. France Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Omalizumab Monoclonal Antibody Biosimilars Sales Market Share by Application (2021-2026)
Figure 78. Egypt Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Omalizumab Monoclonal Antibody Biosimilars Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Omalizumab Monoclonal Antibody Biosimilars in 2026
Figure 84. Manufacturing Process Analysis of Omalizumab Monoclonal Antibody Biosimilars
Figure 85. Industry Chain Structure of Omalizumab Monoclonal Antibody Biosimilars
Figure 86. Channels of Distribution
Figure 87. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Forecast by Region (2027-2032)
Figure 88. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Omalizumab Monoclonal Antibody Biosimilars Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Omalizumab Monoclonal Antibody Biosimilars Revenue Market Share Forecast by Application (2027-2032)
